
Cipla vs Lupin 2027: Same Rs 29,000 Crore Revenue, Very Different Profits and Valuations
Updated: 17 Nov 2026 • 2:17 pm
Posted by:

| Cipla vs Lupin at a glance | Cipla | Lupin |
|---|---|---|
| Share price (16 Nov 2026) | Rs 1,394.50 | Rs 1,976.70 |
| Market cap | Rs 1,12,620 crore | Rs 90,201 crore |
| P/E ratio | 39.47 | 17.28 |
| Q2 FY27 net profit | Rs 856.5 crore | Rs 1,155 crore |
Quick Answer
Cipla vs Lupin compares two large Indian drugmakers that reported almost identical FY26 revenue of about Rs 29,040 crore but very different profits. Lupin earned Rs 5,356 crore of FY26 net profit against Rs 3,870 crore for Cipla. In Q2 FY27, both saw profits fall, with Cipla down 36.7% to Rs 857 crore and Lupin down 22.2% to Rs 1,155 crore. Lupin trades at a P/E of 17.28, while Cipla trades at 39.47.
Cipla vs Lupin in 2027 starts with an unusual fact: both companies reported FY26 revenue of almost exactly Rs 29,040 crore, yet Lupin earned about 38% more net profit and the market values Cipla at more than twice Lupin's P/E. The Cipla vs Lupin margin story explains most of that gap.
Both are among India's largest pharmaceutical companies, with large domestic branded businesses and big US generics operations. Cipla is a Nifty 50 company valued at about Rs 1,12,620 crore, and Lupin is valued at about Rs 90,201 crore. This Cipla vs Lupin comparison covers business models, margins, valuation, Q2 FY27 results, growth drivers, risks and shareholding.
Click Here – Get Free Investment Predictions
Cipla vs Lupin: Company Overview
What Cipla Does
Cipla is a Mumbai-based drugmaker with a strong presence in respiratory medicines, including inhalers, along with anti-infectives, cardiac and chronic therapies. It has large businesses in India, North America and South Africa.
The company is known for its respiratory franchise in India and its complex generics pipeline for the US. Promoters hold 29.21% of the company.
What Lupin Does
Lupin is a Mumbai-based pharmaceutical company with major operations in the US, India and other emerging markets. It makes generics, complex injectables, inhalation products and branded medicines in cardiac, diabetes, respiratory and central nervous system therapies.
The promoter group holds 46.84%. Lupin's US business recovered strongly over the last two years, which lifted its profits well above earlier levels.
How Cipla and Lupin Make Money
Both companies earn revenue in two broad ways. In India, they sell branded generic medicines through doctors and pharmacies, where margins are steady and brand strength matters. In the US, they sell generic and specialty products, where a few complex or limited-competition launches can lift profits sharply for a few years.
Cipla's model leans on its respiratory franchise in India and emerging markets, plus specialty generics in the US. Lupin's model has a larger US weight, so its profits swing more with US product launches and pricing.
This difference shapes Cipla vs Lupin. When high-margin US products are contributing, profits rise fast. When those products face new competition, margins fall back.
Cipla vs Lupin Valuation and Key Metrics
The Cipla vs Lupin table uses market data as of the 16 November 2026 close and trailing twelve month ratios.
| Cipla vs Lupin metric | Cipla | Lupin |
|---|---|---|
| Share price (CMP) | Rs 1,394.50 | Rs 1,976.70 |
| 52-week high | Rs 1,539.70 | Rs 2,529.50 |
| 52-week low | Rs 1,165.70 | Rs 1,892.90 |
| Distance from 52-week high | -9.4% | -21.9% |
| Market capitalisation | Rs 1,12,620 crore | Rs 90,201 crore |
| P/E ratio (TTM) | 39.47 | 17.28 |
| Industry P/E | 40.65 | 40.65 |
| P/B ratio | 3.18 | 3.75 |
| Return on equity (ROE) | 8.18% | 21.65% |
| Debt to equity | 0.02 | 0.26 |
| Dividend yield | 0.93% | 0.91% |
| FY26 revenue | Rs 29,045 crore | Rs 29,039 crore |
| FY26 net profit | Rs 3,870 crore | Rs 5,355 crore |
The Cipla vs Lupin table shows Lupin trading at a P/E of 17.28 against 39.47 for Cipla. The pharma industry P/E is 40.65, so Cipla trades close to the sector and Lupin well below it.
Lupin has a much higher return on equity at 21.65% against 8.18% for Cipla. Both have low debt, with debt to equity of 0.26 for Lupin and 0.02 for Cipla. Dividend yields are similar at about 0.9%.
FY26 is where the gap shows most clearly. Revenue was Rs 29,045 crore for Cipla and Rs 29,039 crore for Lupin, but Lupin's net profit was Rs 5,356 crore against Rs 3,870 crore for Cipla.
Cipla vs Lupin Q2 FY27 Results Compared
Figures below are consolidated revenue and net profit for the quarter ended 30 September 2026.
| Cipla vs Lupin Q2 FY27 (Sep 2026 quarter) | Cipla | Lupin |
|---|---|---|
| Revenue Q2 FY27 | Rs 7,555 crore | Rs 7,954 crore |
| Revenue Q2 FY26 | Rs 7,858 crore | Rs 7,138 crore |
| Revenue change YoY | -3.9% | +11.4% |
| Net profit Q2 FY27 | Rs 856.5 crore | Rs 1,155 crore |
| Net profit Q2 FY26 | Rs 1,353 crore | Rs 1,485 crore |
| Net profit change YoY | -36.7% | -22.2% |
| Net profit Q1 FY27 | Rs 787.1 crore | Rs 1,417 crore |
In the Q2 FY27 results, Cipla's revenue fell 3.9% to Rs 7,555 crore and net profit fell 36.7% to Rs 857 crore. Its operating margin dropped to 20.9% from 29.1% a year earlier, though profit improved from Rs 787 crore in the June quarter.
Lupin's revenue rose 11.4% to Rs 7,954 crore, but net profit fell 22.2% to Rs 1,155 crore. Its operating margin fell to 27.9% from 35.6%, and profit was below the Rs 1,417 crore of Q1 FY27.
For Cipla vs Lupin, both companies saw margins come off their peaks. Cipla's drop was sharper, while Lupin still earns a higher margin and kept revenue growing.
Cipla vs Lupin Margins: What Matters in 2027
Cipla: rebuilding US margins
Cipla's operating margin fell about 8 points in a year, which points to pressure on the higher-margin parts of its US business. Its 2027 path depends on new complex generic and respiratory launches in the US and steady growth in India and South Africa.
The stock trades about 9.4% below its 52-week high of Rs 1,539.70, which suggests the market expects a recovery rather than a long decline.
Lupin: holding on to a higher base
Lupin's FY26 profit jumped about 62% from FY25 as its US business scaled up. The challenge for 2027 is keeping margins high as some products face more competition. Its revenue growth of 11.4% in Q2 FY27 shows the top line is still expanding.
In Cipla vs Lupin, Lupin's low P/E reflects market doubt about how long its peak margins last. Its share price of Rs 1,976.70 is close to the 52-week low of Rs 1,892.90.
Domestic market as the anchor
Both companies have large Indian branded businesses that grow steadily regardless of US pricing. Chronic therapies such as cardiac, diabetes and respiratory are expected to keep growing faster than the overall market, which supports both companies. The Nifty 500 tracks the broader market both belong to.
Compare pharma stocks on the Univest Screener
Risks in Cipla vs Lupin
Risks for Cipla
Cipla's main risk is continued margin pressure in the US, which already cut its Q2 FY27 profit by 36.7%. With a P/E of 39.47, the stock needs a margin recovery to hold its valuation. Foreign institutions reduced their stake from 24.55% to 20.25%.
Risks for Lupin
In the Cipla vs Lupin risk check, Lupin's main risk is the fade of high-margin US products. Its profit has already slipped from the June quarter. US regulatory inspections of plants are a risk for both companies but matter more for Lupin's larger US share.
Cipla vs Lupin Shareholding
| Cipla vs Lupin shareholding (Sep '26, change vs Sep '25) | Cipla | Lupin |
|---|---|---|
| Promoters | 29.21% (+0.00 pts) | 46.84% (-0.06 pts) |
| Foreign institutions (FII) | 20.25% (-4.30 pts) | 23.28% (+2.79 pts) |
| Domestic institutions (DII) | 34.94% (+4.69 pts) | 23.78% (-2.77 pts) |
| Public and others | 15.61% (-0.38 pts) | 6.09% (+0.03 pts) |
Cipla promoters hold 29.21%, unchanged over the year. Domestic institutions raised their stake from 30.25% to 34.94% as foreign institutions sold.
Lupin promoters hold 46.84%. Foreign institutions raised their stake from 20.49% to 23.28%, while domestic institutions cut theirs to 23.78%. In Cipla vs Lupin, foreign and domestic funds moved in opposite directions in each stock.
Download the Univest iOS App or Univest Android App to track Cipla and Lupin live and read daily pharma sector research.
Which Investor Does Each Pharma Stock Suit?
Cipla suits investors who value franchise strength
Within Cipla vs Lupin, Cipla fits investors who want a respiratory-led pharma franchise with very low debt and strong domestic brands. They should accept a P/E near 39 while margins rebuild.
Lupin suits value-focused pharma investors
Lupin fits investors who want higher current profitability and ROE at a P/E below the sector. They need to accept the risk that US margins come down further.
Final View on Cipla vs Lupin
Cipla vs Lupin shows how two companies with the same FY26 revenue can earn very different profits. Lupin made Rs 5,356 crore and has an ROE of 21.65%, while Cipla made Rs 3,870 crore with an ROE of 8.18%, yet Cipla trades at more than twice Lupin's P/E.
Both saw margins fall in Q2 FY27. The Cipla vs Lupin decision depends on whether an investor trusts Cipla's margin recovery or Lupin's ability to hold its higher base. US launches and domestic growth through 2027 will settle the debate.
Disclaimer: Data and figures in this article are drawn from publicly available information and company disclosures, and they may change after publication. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Cipla vs Lupin
Why did Cipla's profit fall in Q2 FY27?
Ans. Cipla's net profit fell 36.7% to Rs 857 crore in Q2 FY27, while revenue fell 3.9% to Rs 7,555 crore. Its operating margin dropped to 20.9% from 29.1% a year earlier. This points to pressure on higher-margin US products. Profit did improve from Rs 787 crore in the June quarter.
Did Lupin's revenue grow in Q2 FY27?
Ans. Yes, Lupin's revenue rose 11.4% to Rs 7,954 crore in Q2 FY27. Its net profit fell 22.2% to Rs 1,155 crore as the operating margin dropped to 27.9% from 35.6%. Lupin still earns a higher margin than Cipla. Profit was below the June quarter's Rs 1,417 crore.
Why is Cipla's P/E higher than Lupin's?
Ans. Cipla trades at a P/E of 39.47 and Lupin at 17.28. The market expects Cipla's earnings to recover from a lower base, which raises its multiple. Lupin's lower P/E reflects doubts about how long its high US margins can last. The pharma industry P/E is 40.65.
Which company had higher FY26 profit?
Ans. Lupin's FY26 net profit was Rs 5,356 crore against Rs 3,870 crore for Cipla. Both reported revenue of about Rs 29,040 crore. Lupin's profit grew about 62% from FY25, while Cipla's fell from Rs 5,291 crore. The difference came from margins.
What is the ROE of Cipla and Lupin?
Ans. Lupin has a return on equity of 21.65%, while Cipla's ROE is 8.18%. Lupin earns more on its equity because of its higher profit. Both have low debt, with Cipla almost debt-free. ROE is one of several ratios used to compare drugmakers.
How far are both stocks from their 52-week highs?
Ans. Cipla closed at Rs 1,394.50 on 16 November 2026, about 9.4% below its 52-week high of Rs 1,539.70. Lupin closed at Rs 1,976.70, about 21.9% below its high of Rs 2,529.50. Lupin is close to its 52-week low of Rs 1,892.90. Prices change daily.
Is Cipla vs Lupin a buy or sell decision?
Ans. This Cipla vs Lupin comparison is educational and does not give a buy or sell call. Cipla offers a strong respiratory franchise at a P/E of 39.47, and Lupin offers higher ROE at a P/E of 17.28. Both face US margin risk. Investors should consult a SEBI-registered adviser before deciding.
Recent Articles

Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
17 November 2026

Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
17 November 2026

AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
17 November 2026

A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
17 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
63 moons technologies Analyst Review 2027: Cyber Arm Lifts Guidance to ₹600 Crore, But the Group Still Loses Money
Popular this week
5Paisa Capital Analyst Review 2027: Revenue Up 12%, Profit Down 26% and an MTF Book Growing 32%

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





